There is no intervention. Patients will stop their tyrosine kinase inhibitor yielding to 2 subsets: patients with or without the TKI withdrawal syndrome.

Plasma samples, if not used, will be kept frozen for further exploration if necessary.

Chronic Myeloid Leukemia

Tyrosine Kinase Inhibitor

Withdrawal Syndrome

University hospital

Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients: Observatory Trial Studying the Biological Factors.

Etude Observationnelle Biologique Sur le Syndrome de Sevrage Des Inhibiteurs de Tyrosine Kinase Dans la Leucémie Myéloïde Chronique.

Measurement of cytokines: A variation of 20% in a given marker will be significant if it is observed in the group with "TKI WS" but not in the group without "TKI WS". Of note, the patient will be his own witness.
. In picogram/milliliter (pg/ml): IL2,IL 6, IL10, IL15, TGFβ,TNFα, IFNγ, VEGF, PDGFβ,

In nanogram/milliliter (ng/ml) : Osteoprotegerin

In international Unit/ liter (IU/l) Rheumatoid factor,

In international Unit/ liter (IU/l) Creatinine phosphokinase

It will help to define the WS thanks to the calculation of the score of pain intensity. The score will be checked at the time the TKI is stopped (baseline) and then every month. Any increase of at least 2 points compared to the baseline will be significant enough to conclude to the TKI WS.
Pain intensity score is the mean of the scores of the four following questions in which the number 0 confers to "No pain" and 10 to "Pain as bad as the patient can imagine":
Please rate your pain by marking the box beside the number that best describes your pain at its worst in the last week.
Please rate your pain by marking the box beside the number that best describes your pain at its least in the last week
Please rate your pain by marking the box beside the number that best describes your pain on average
Please rate your pain by marking the box beside the number that tells how much pain you have right now

It derives from the McGill questionnaire and describes the type of pain rated by the patient: None = 0; Mild = 1 Moderate =2 Severe = 3. It will complete the BPI questionnaire by giving precision on the type of pain:
-Throbbing, Shooting, Stabbing, Sharp ...

It will explore the quality of life every 3 months

hypophosphatemia/tyrosine

Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients: Observatory Trial Studying the Biological Factors.

Najkompletnejšia databáza liečivých bylín podporovaná vedou